Literature DB >> 23540741

Cardiovascular toxicities of cancer chemotherapy.

Raphael Bonita1, Rajesh Pradhan.   

Abstract

Cancer chemotherapy has improved over the years with the advent of newer agents, including more targeted chemotherapeutic drugs, resulting in better patient survival. However, with continued use and patient exposure to these drugs, important cardiovascular adverse effects are becoming realized, such as left ventricular dysfunction and heart failure, myocardial ischemia, hypertension, arrhythmias, and pulmonary arterial hypertension. In this article, we review the most common cardiovascular toxicities and their related pathophysiology that occur with the use of these agents.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23540741     DOI: 10.1053/j.seminoncol.2013.01.004

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  10 in total

Review 1.  Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy.

Authors:  Nicole S Klee; Cameron G McCarthy; Patricia Martinez-Quinones; R Clinton Webb
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-09-15

Review 2.  A strategy for integrating essential three-dimensional microphysiological systems of human organs for realistic anticancer drug screening.

Authors:  Christopher Heylman; Agua Sobrino; Venktesh S Shirure; Christopher Cw Hughes; Steven C George
Journal:  Exp Biol Med (Maywood)       Date:  2014-04-16

3.  Live birth outcomes after adolescent and young adult breast cancer.

Authors:  Chelsea Anderson; Stephanie M Engel; Carey K Anders; Hazel B Nichols
Journal:  Int J Cancer       Date:  2018-01-04       Impact factor: 7.396

4.  Risk of Adverse Obstetric Outcomes and the Abnormal Growth of Offspring in Women with a History of Thyroid Cancer.

Authors:  Geum Joon Cho; So-Youn Kim; Hoi Chang Lee; Kyu-Min Lee; Sung Won Han; Min-Jeong Oh; Teresa K Woodruff
Journal:  Thyroid       Date:  2019-05-09       Impact factor: 6.568

5.  Birth Outcomes Among Adolescent and Young Adult Cancer Survivors.

Authors:  Chelsea Anderson; Stephanie M Engel; Jennifer E Mersereau; Kristin Z Black; William A Wood; Carey K Anders; Hazel B Nichols
Journal:  JAMA Oncol       Date:  2017-08-01       Impact factor: 31.777

6.  The 10th Biennial Hatter Cardiovascular Institute workshop: cellular protection-evaluating new directions in the setting of myocardial infarction, ischaemic stroke, and cardio-oncology.

Authors:  Sean M Davidson; Sapna Arjun; Maryna V Basalay; Robert M Bell; Daniel I Bromage; Hans Erik Bøtker; Richard D Carr; John Cunningham; Arjun K Ghosh; Gerd Heusch; Borja Ibanez; Petra Kleinbongard; Sandrine Lecour; Helen Maddock; Michel Ovize; Malcolm Walker; Marlene Wiart; Derek M Yellon
Journal:  Basic Res Cardiol       Date:  2018-10-11       Impact factor: 17.165

7.  The Adolescent and Young Adult (AYA) Horizon Study: An AYA Cancer Survivorship Cohort.

Authors:  Chun R Chao; Lawrence H Kushi; Hazel B Nichols; Chris D Baggett; Stephanie M Engel; Darios Getahun; Chelsea Anderson; Nancy T Cannizzaro; Laura Green; Parul Gupta; Cecile A Laurent; Paul C Lin; Clare Meernik; Lisa M Moy; Ethan Wantman; Lanfang Xu; Marilyn L Kwan; Jennifer E Mersereau
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-02-22       Impact factor: 4.090

Review 8.  Getting to the Heart of the Matter: An Overview of Cardiac Toxicity Related to Cancer Therapy.

Authors:  Carine E Hamo; Michelle Weisfelner Bloom
Journal:  Clin Med Insights Cardiol       Date:  2015-08-02

9.  Cardiac dysfunction among soft tissue sarcoma patients in Denmark.

Authors:  Sumitra Shantakumar; Morten Olsen; Thao T Vo; Mette Nørgaard; Lars Pedersen
Journal:  Clin Epidemiol       Date:  2016-04-15       Impact factor: 4.790

10.  Redox-Responsive Disulfide Bond-Bridged mPEG-PBLA Prodrug Micelles for Enhanced Paclitaxel Biosafety and Antitumor Efficacy.

Authors:  Sheng Chang; Yanfei Wang; Tianyi Zhang; Xiaohui Pu; Lanlan Zong; Heyun Zhu; Luling Zhao; Bo Feng
Journal:  Front Oncol       Date:  2019-08-27       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.